Skip to main content
Top
Published in: Clinical Pharmacokinetics 4/2014

01-04-2014 | Review Article

Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings

Author: Iftekhar Mahmood

Published in: Clinical Pharmacokinetics | Issue 4/2014

Login to get access

Abstract

It should be recognized that children are not small adults, hence dosing in children should not be a ‘small adult dose’. A mean population dose in all age groups is just an average dose and not necessarily the best or the correct dose for a given patient. The dose of a drug varies from patient to patient and individual adjustment of the dose is always ideal but is not always practical. Theoretically, dose selection in paediatric drug development or clinical settings can be done by using either body weight or the clearance of a drug. Over the years, a lot of approaches have been suggested for the prediction of drug clearance or dose in paediatrics. Although some proposed methods are useful for the prediction of clearance or dose in children, there remains a high degree of uncertainty in the prediction of drug clearance or dose in children. In particular, the prediction of clearance or dose in an individual patient remains highly erratic. This review takes a critical look at these approaches and highlights the application and limitations of these proposed methods.
Literature
1.
go back to reference Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.PubMed Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.PubMed
2.
go back to reference Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight and age. Ther Drug Monit. 2007;29:271–8.PubMed Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight and age. Ther Drug Monit. 2007;29:271–8.PubMed
3.
go back to reference Weiss CF, Glazko A, Weston JK. Chloramphenicol in the new born infant. N Engl J Med. 1960;262:787–94.PubMed Weiss CF, Glazko A, Weston JK. Chloramphenicol in the new born infant. N Engl J Med. 1960;262:787–94.PubMed
4.
go back to reference Silverman WA, Anderson DH, Blanc WA, et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic anti-bacterial regimens. Pediatrics. 1956;18:614–25.PubMed Silverman WA, Anderson DH, Blanc WA, et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic anti-bacterial regimens. Pediatrics. 1956;18:614–25.PubMed
5.
go back to reference Gibaldi M. Gastrointestinal absorption: physicochemical considerations. In: Biopharmaceutics and clinical pharmacokinetics. 3rd ed. Philadelphia: Lea and Febiger; 1984. p. 44–63. Gibaldi M. Gastrointestinal absorption: physicochemical considerations. In: Biopharmaceutics and clinical pharmacokinetics. 3rd ed. Philadelphia: Lea and Febiger; 1984. p. 44–63.
6.
go back to reference Huang NN, High RH. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr. 1953;42:657–68.PubMed Huang NN, High RH. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr. 1953;42:657–68.PubMed
7.
go back to reference Linday L, Dobkin JF, Wang TC, et al. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics. 1987;79:544–8.PubMed Linday L, Dobkin JF, Wang TC, et al. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics. 1987;79:544–8.PubMed
8.
go back to reference Rutter N. Percutaneous drug absorption in the newborn: hazards and uses. Clin Perinatol. 1987;14:911–30.PubMed Rutter N. Percutaneous drug absorption in the newborn: hazards and uses. Clin Perinatol. 1987;14:911–30.PubMed
9.
go back to reference Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics. 1961;28:169–81.PubMed Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics. 1961;28:169–81.PubMed
10.
go back to reference McNammara PJ, Alcorn J. Protein binding predictions in infants. AAPS Pharm Sci. 2002;4:1–8. McNammara PJ, Alcorn J. Protein binding predictions in infants. AAPS Pharm Sci. 2002;4:1–8.
11.
go back to reference Blanco JG, Harrison PL, Evans WE, et al. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos. 2000;28:379–82.PubMed Blanco JG, Harrison PL, Evans WE, et al. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos. 2000;28:379–82.PubMed
12.
go back to reference Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam. 1998;15:45–51.PubMed Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam. 1998;15:45–51.PubMed
13.
go back to reference Pacifici GM, Franchi M, Colizzi C, et al. Glutathione S-transferase in humans: development and tissue distribution. Arch Toxicol. 1988;6:265–9. Pacifici GM, Franchi M, Colizzi C, et al. Glutathione S-transferase in humans: development and tissue distribution. Arch Toxicol. 1988;6:265–9.
14.
go back to reference Levy G, Khanna NN, Soda DM, et al. Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and d-glucaric acid excretion. Pediatrics. 1975;55:818–25.PubMed Levy G, Khanna NN, Soda DM, et al. Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and d-glucaric acid excretion. Pediatrics. 1975;55:818–25.PubMed
15.
go back to reference McRorie TI, Lynn AM, Nespeca MK, et al. The maturation of morphine clearance and metabolism. AJDC. 1992;146:972–6.PubMed McRorie TI, Lynn AM, Nespeca MK, et al. The maturation of morphine clearance and metabolism. AJDC. 1992;146:972–6.PubMed
16.
go back to reference Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatr Rev. 1998;19:423–8.PubMed Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatr Rev. 1998;19:423–8.PubMed
17.
go back to reference Shargel L, Yu ABC. Drug clearance. In: Introduction to pharmacokinetics: applied biopharmaceutics and pharmacokinetics. 3rd ed. Norwalk, Appleton & Lange; 1993. p. 265–92. Shargel L, Yu ABC. Drug clearance. In: Introduction to pharmacokinetics: applied biopharmaceutics and pharmacokinetics. 3rd ed. Norwalk, Appleton & Lange; 1993. p. 265–92.
18.
go back to reference Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 1978;92:705–12.PubMed Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 1978;92:705–12.PubMed
19.
go back to reference Brown RD, Campoli-Richards M. Antimicrobial therapy in neonates, infants and children. Clin Pharmacokinet. 1989;17:105–15.PubMed Brown RD, Campoli-Richards M. Antimicrobial therapy in neonates, infants and children. Clin Pharmacokinet. 1989;17:105–15.PubMed
20.
go back to reference Jacobs RF, Kearns GL, Brown AL, et al. Renal clearance of imipenem in children. Eur J Microbiol. 1984;3:471–4. Jacobs RF, Kearns GL, Brown AL, et al. Renal clearance of imipenem in children. Eur J Microbiol. 1984;3:471–4.
21.
go back to reference Gibaldi M. Drug disposition-elimination. In: Biopharmaceutics and clinical pharmacokinetics. 3rd ed. Philadelphia, Lea & Febiger; 1984. p. 181–205. Gibaldi M. Drug disposition-elimination. In: Biopharmaceutics and clinical pharmacokinetics. 3rd ed. Philadelphia, Lea & Febiger; 1984. p. 181–205.
22.
go back to reference Jones DP, Chesney RW. Development of tubular function. Clin Perinatol. 1992;19:33–57.PubMed Jones DP, Chesney RW. Development of tubular function. Clin Perinatol. 1992;19:33–57.PubMed
23.
go back to reference Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002;41:959–98.PubMed Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002;41:959–98.PubMed
24.
go back to reference Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet. 2002;41:1077–94.PubMed Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet. 2002;41:1077–94.PubMed
25.
go back to reference Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS Pharm Sci 2000;2:article 3 (1–7). Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS Pharm Sci 2000;2:article 3 (1–7).
26.
go back to reference Hayton WL, Kneer J, de Groot R, et al. Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants. Antimicrob Agents Chemother. 1996;40:567–74.PubMedCentralPubMed Hayton WL, Kneer J, de Groot R, et al. Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants. Antimicrob Agents Chemother. 1996;40:567–74.PubMedCentralPubMed
27.
go back to reference Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev. 1984;15:1071–121.PubMed Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev. 1984;15:1071–121.PubMed
28.
go back to reference Mahmood I. Introduction to allometry. In: Interspecies pharmacokinetic scaling: principles and application of allometric scaling. Rockville: Pine House Publishers; 2012. p. 23–38. Mahmood I. Introduction to allometry. In: Interspecies pharmacokinetic scaling: principles and application of allometric scaling. Rockville: Pine House Publishers; 2012. p. 23–38.
29.
go back to reference Mahmood I. Prediction of drug clearance in children from adult clearance: allometric scaling versus exponent 0.75. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 41–55. Mahmood I. Prediction of drug clearance in children from adult clearance: allometric scaling versus exponent 0.75. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 41–55.
30.
go back to reference Mahmood I. Prediction of drug clearance in children (≤5 years) by Boxenbaum coefficient methods. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 64–77. Mahmood I. Prediction of drug clearance in children (≤5 years) by Boxenbaum coefficient methods. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 64–77.
31.
go back to reference Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res. 1991;20:1–116. Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res. 1991;20:1–116.
32.
go back to reference Kleiber M. Body size and metabolism. Hilgardia. 1932;6:315. Kleiber M. Body size and metabolism. Hilgardia. 1932;6:315.
33.
go back to reference Kleiber M. Body size and metabolic rate. Physiol Rev. 1947;4:511–41. Kleiber M. Body size and metabolic rate. Physiol Rev. 1947;4:511–41.
34.
go back to reference Brody S, Procter RC, Ashworth US. Basal metabolism, endogenous nitrogen, creatinine and neutral sulphur excretions as functions of body weight. Univ Missouri Agric Exp Stn Res Bull. 1934;220:1–40. Brody S, Procter RC, Ashworth US. Basal metabolism, endogenous nitrogen, creatinine and neutral sulphur excretions as functions of body weight. Univ Missouri Agric Exp Stn Res Bull. 1934;220:1–40.
35.
go back to reference Savage VM, Gillooly JF, Woodruff WH, et al. The predominance of quarter-power scaling in biology. Funct Ecol. 2004;18:257–82. Savage VM, Gillooly JF, Woodruff WH, et al. The predominance of quarter-power scaling in biology. Funct Ecol. 2004;18:257–82.
36.
go back to reference Feldman HA, McMahon TA. The ¾ mass exponent for energy metabolism is not a statistical artifact? Resp Physiol. 1983;52:149–63. Feldman HA, McMahon TA. The ¾ mass exponent for energy metabolism is not a statistical artifact? Resp Physiol. 1983;52:149–63.
37.
go back to reference Heusner AA. Energy metabolism and body size I. Is the 0.75 mass exponent of Kleiber’s equation a statistical artifact? Resp Physiol. 1982;48:13–25. Heusner AA. Energy metabolism and body size I. Is the 0.75 mass exponent of Kleiber’s equation a statistical artifact? Resp Physiol. 1982;48:13–25.
38.
go back to reference Hayssen V, Lacy RC. Basal metabolic rates in mammals: taxonomic differences in the allometry of BMR and body mass. Comp Biochem Physiol. 1985;81A:741–54. Hayssen V, Lacy RC. Basal metabolic rates in mammals: taxonomic differences in the allometry of BMR and body mass. Comp Biochem Physiol. 1985;81A:741–54.
39.
go back to reference West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122–6.PubMed West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122–6.PubMed
40.
go back to reference Kozłowski J, Konarzewski M. Is West, Brown and Enquist’s model of allometric scaling mathematically correct and biologically relevant? Funct Ecol. 2004;18:283–9. Kozłowski J, Konarzewski M. Is West, Brown and Enquist’s model of allometric scaling mathematically correct and biologically relevant? Funct Ecol. 2004;18:283–9.
41.
go back to reference Kozłowski J, Konarzewski M. West, Brown and Enquist’s model of allometric scaling again: the same questions remain. Funct Ecol. 2005;19:739–43. Kozłowski J, Konarzewski M. West, Brown and Enquist’s model of allometric scaling again: the same questions remain. Funct Ecol. 2005;19:739–43.
42.
go back to reference Painter PR. The fractal geometry of nutrient exchange surfaces does not provide an explanation for 3/4-power metabolic scaling. Theor Biol Med Model. 2005;2:30.PubMedCentralPubMed Painter PR. The fractal geometry of nutrient exchange surfaces does not provide an explanation for 3/4-power metabolic scaling. Theor Biol Med Model. 2005;2:30.PubMedCentralPubMed
43.
go back to reference Petit G, Anfodillo T. Plant physiology in theory and practice: an analysis of the WBE model for vascular plants. J Theor Biol. 2009;259:1–4.PubMed Petit G, Anfodillo T. Plant physiology in theory and practice: an analysis of the WBE model for vascular plants. J Theor Biol. 2009;259:1–4.PubMed
44.
go back to reference Glazier DS. Beyond the ‘3/4-power law’: variation in the intra- and interspecific scaling of metabolic rate in animals. Biol Rev Camb Philos Soc. 2005;80:611–62.PubMed Glazier DS. Beyond the ‘3/4-power law’: variation in the intra- and interspecific scaling of metabolic rate in animals. Biol Rev Camb Philos Soc. 2005;80:611–62.PubMed
45.
go back to reference White CR, Cassey P, Blackburn TM. Allometric exponents do not support a universal metabolic allometry. Ecology. 2007;88:315–23.PubMed White CR, Cassey P, Blackburn TM. Allometric exponents do not support a universal metabolic allometry. Ecology. 2007;88:315–23.PubMed
46.
go back to reference Packard GC, Birchard GF. Traditional allometric analysis fails to provide a valid predictive model for mammalian metabolic rates. J Exp Biol. 2008;211(Pt 22):3581–7.PubMed Packard GC, Birchard GF. Traditional allometric analysis fails to provide a valid predictive model for mammalian metabolic rates. J Exp Biol. 2008;211(Pt 22):3581–7.PubMed
47.
go back to reference Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci. 2010;99:2927–33.PubMed Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci. 2010;99:2927–33.PubMed
48.
go back to reference Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metab Drug Interact. 2009;24:57–81. Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metab Drug Interact. 2009;24:57–81.
49.
go back to reference West D, West BJ. Physiologic time: a hypothesis. Phys Life Rev. 2013;10:210–24.PubMed West D, West BJ. Physiologic time: a hypothesis. Phys Life Rev. 2013;10:210–24.PubMed
50.
go back to reference Bentley LP, Stegen JC, Savage VM, et al. An empirical assessment of tree branching networks and implications for plant allometric scaling models. Ecol Lett. 2013;16:1069–78.PubMed Bentley LP, Stegen JC, Savage VM, et al. An empirical assessment of tree branching networks and implications for plant allometric scaling models. Ecol Lett. 2013;16:1069–78.PubMed
51.
go back to reference White CR, Seymour RS. Mammalian basal metabolic rate is proportional to body mass 2/3. Proc Natl Acad Sci USA. 2003;100:4046–9.PubMedCentralPubMed White CR, Seymour RS. Mammalian basal metabolic rate is proportional to body mass 2/3. Proc Natl Acad Sci USA. 2003;100:4046–9.PubMedCentralPubMed
52.
go back to reference McLeay SC, Morrish GA, Kirkpatrick CM, et al. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51:319–30.PubMed McLeay SC, Morrish GA, Kirkpatrick CM, et al. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51:319–30.PubMed
53.
go back to reference Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in pediatric patients. Clin Pharmacokinet. 1997;33:313–27.PubMed Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in pediatric patients. Clin Pharmacokinet. 1997;33:313–27.PubMed
54.
go back to reference Peeters MY, Allegaert K, Blussé van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet. 2010;49:269–75.PubMed Peeters MY, Allegaert K, Blussé van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet. 2010;49:269–75.PubMed
55.
go back to reference Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet. 2006;45:1–11.PubMed Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet. 2006;45:1–11.PubMed
56.
go back to reference Edginton AN, Shah B, Sevestre M, et al. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Clin Pharmacokinet. 2013;52:693–703.PubMed Edginton AN, Shah B, Sevestre M, et al. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Clin Pharmacokinet. 2013;52:693–703.PubMed
57.
go back to reference Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr. 2013 (Epub ahead of print). Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr. 2013 (Epub ahead of print).
58.
go back to reference Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102:2941–52.PubMed Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102:2941–52.PubMed
59.
go back to reference Balan G, Thompson GA, Gibb R, et al. Doxylamine pharmacokinetics following single dose oral administration in children ages 2–17 years. J Clin Pharmacol. 2013. Balan G, Thompson GA, Gibb R, et al. Doxylamine pharmacokinetics following single dose oral administration in children ages 2–17 years. J Clin Pharmacol. 2013.
60.
go back to reference Mahmood I. Allometric exponents and population pharmacokinetics: a single or body weight dependent exponents. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers. p. 88–100; 2013. Mahmood I. Allometric exponents and population pharmacokinetics: a single or body weight dependent exponents. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers. p. 88–100; 2013.
61.
go back to reference Mahmood I. Prediction of drug clearance in preterm and term neonates: different exponents for different age groups? In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 88–100. Mahmood I. Prediction of drug clearance in preterm and term neonates: different exponents for different age groups? In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 88–100.
62.
go back to reference Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol. 2006;61:545–57.PubMedCentralPubMed Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol. 2006;61:545–57.PubMedCentralPubMed
63.
go back to reference Mahmood I. Prediction of drug clearance in children 3 months and younger: an allometric approach. Drug Metab Drug Interact. 2010;25:25–34. Mahmood I. Prediction of drug clearance in children 3 months and younger: an allometric approach. Drug Metab Drug Interact. 2010;25:25–34.
64.
go back to reference Knibbe CA, Zuideveld KP, Aarts LP, et al. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol. 2005;59:705–11.PubMedCentralPubMed Knibbe CA, Zuideveld KP, Aarts LP, et al. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol. 2005;59:705–11.PubMedCentralPubMed
65.
go back to reference Mahmood I. Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor. Clin Pharmacokinet. 2010;49:479–92.PubMed Mahmood I. Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor. Clin Pharmacokinet. 2010;49:479–92.PubMed
66.
go back to reference Johnson TN. The problems in scaling adult drug doses to children. Arch Dis Child. 2008;93:207–11.PubMed Johnson TN. The problems in scaling adult drug doses to children. Arch Dis Child. 2008;93:207–11.PubMed
67.
68.
go back to reference Nahata MC. Lack of pediatric drug formulations. Pediatrics. 1999;104:607–9.PubMed Nahata MC. Lack of pediatric drug formulations. Pediatrics. 1999;104:607–9.PubMed
69.
go back to reference Matsui D, Baron A, Rieder MJ. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacother. 1996;30:586–8.PubMed Matsui D, Baron A, Rieder MJ. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacother. 1996;30:586–8.PubMed
70.
go back to reference Kee JL, Marshall SM. Calculations for specialty areas. In: Clinical calculations: with applications to general and specialty areas. 7th ed. St Louis: Elseviers (Saunders); 2012. p. 240–69. Kee JL, Marshall SM. Calculations for specialty areas. In: Clinical calculations: with applications to general and specialty areas. 7th ed. St Louis: Elseviers (Saunders); 2012. p. 240–69.
71.
go back to reference Munzenberger PJ, McKercher P. Pediatric dosing—the pharmacist’s dilemma. Contemp Pharm Pract. 1980;3(1):11–4.PubMed Munzenberger PJ, McKercher P. Pediatric dosing—the pharmacist’s dilemma. Contemp Pharm Pract. 1980;3(1):11–4.PubMed
72.
go back to reference Lack JA, Stuart-Taylor ME. Calculation of drug dosage and body surface area of children. Br J Anaesth. 1997;78:601–5.PubMed Lack JA, Stuart-Taylor ME. Calculation of drug dosage and body surface area of children. Br J Anaesth. 1997;78:601–5.PubMed
73.
go back to reference Mahmood I. Dose selection in children: allometry and other methods. In: Pediatric pharmacology and pharmacokinetics. Rockville: Pine House Publishers; 2008. p. 184–216. Mahmood I. Dose selection in children: allometry and other methods. In: Pediatric pharmacology and pharmacokinetics. Rockville: Pine House Publishers; 2008. p. 184–216.
74.
go back to reference Mahmood I. Dose selection in children. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 151–60. Mahmood I. Dose selection in children. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 151–60.
75.
go back to reference Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819–29.PubMed Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819–29.PubMed
76.
go back to reference Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology. 2000;92:727–38.PubMed Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology. 2000;92:727–38.PubMed
77.
go back to reference Peeters MY, Prins SA, Knibbe CA, et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology. 2006;104:466–74.PubMed Peeters MY, Prins SA, Knibbe CA, et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology. 2006;104:466–74.PubMed
78.
go back to reference Aumente D, Buelga DS, Lukas JC, et al. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45:1227–38.PubMed Aumente D, Buelga DS, Lukas JC, et al. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45:1227–38.PubMed
79.
go back to reference Cella M, Zhao W, Jacqz-Aigrain E, et al. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol. 2011;72:454–64.PubMedCentralPubMed Cella M, Zhao W, Jacqz-Aigrain E, et al. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol. 2011;72:454–64.PubMedCentralPubMed
80.
go back to reference Santen G, Horrigan J, Danhof M, et al. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther. 2009;86:255–62.PubMed Santen G, Horrigan J, Danhof M, et al. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther. 2009;86:255–62.PubMed
81.
go back to reference Anand KJ, Anderson BJ, Holford NH, NEOPAIN Trial Investigators Group, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth. 2008;101:680–9.PubMedCentralPubMed Anand KJ, Anderson BJ, Holford NH, NEOPAIN Trial Investigators Group, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth. 2008;101:680–9.PubMedCentralPubMed
82.
go back to reference Anderson BJ. Pediatric models for adult target-controlled infusion pumps. Paediatr Anaesth. 2010;20:223–32.PubMed Anderson BJ. Pediatric models for adult target-controlled infusion pumps. Paediatr Anaesth. 2010;20:223–32.PubMed
83.
go back to reference Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth. 2011;21(3):302–8.PubMed Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth. 2011;21(3):302–8.PubMed
84.
go back to reference Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25–36.PubMed Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25–36.PubMed
85.
go back to reference Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol. 2011;71:88–94.PubMedCentralPubMed Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol. 2011;71:88–94.PubMedCentralPubMed
86.
go back to reference Mahmood I. Response to the comments of Professors Anderson & Holford. Br J Clin Pharmacol. 2011;72(3):521–3.PubMedCentral Mahmood I. Response to the comments of Professors Anderson & Holford. Br J Clin Pharmacol. 2011;72(3):521–3.PubMedCentral
87.
go back to reference Mahmood I. Evaluation of sigmoidal maturation and allometric models: prediction of propofol clearance in neonates and infants. Am J Ther. 2013;20:21–8.PubMed Mahmood I. Evaluation of sigmoidal maturation and allometric models: prediction of propofol clearance in neonates and infants. Am J Ther. 2013;20:21–8.PubMed
88.
go back to reference Anderson BJ, Holford NH. Tips and traps analyzing pediatric pharmacokinetics data. Paediatr Anaesth. 2011;21:222–37.PubMed Anderson BJ, Holford NH. Tips and traps analyzing pediatric pharmacokinetics data. Paediatr Anaesth. 2011;21:222–37.PubMed
89.
go back to reference Wang C, Allegaert K, Peeters MY, et al. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol. 2013 (Epub ahead of print). Wang C, Allegaert K, Peeters MY, et al. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol. 2013 (Epub ahead of print).
90.
go back to reference Wang C, Sadhavisvam S, Krekels EH, et al. Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig. 2013;33:523–34.PubMed Wang C, Sadhavisvam S, Krekels EH, et al. Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig. 2013;33:523–34.PubMed
91.
go back to reference Wang C, Peeters MY, Allegaert K, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012;29:1570–81.PubMedCentralPubMed Wang C, Peeters MY, Allegaert K, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012;29:1570–81.PubMedCentralPubMed
92.
go back to reference Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51:331–45.PubMed Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51:331–45.PubMed
93.
go back to reference Wang C, Allegaert K, Tibboel D, et al. Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. J Clin Pharmacol. 2013 (Epub ahead of print). Wang C, Allegaert K, Tibboel D, et al. Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. J Clin Pharmacol. 2013 (Epub ahead of print).
94.
go back to reference Wieser W. A distinction must be made between the ontogeny and the phylogeny of metabolism in order to understand the mass exponent of energy metabolism. Resp Physiol. 1984;55:1–9. Wieser W. A distinction must be made between the ontogeny and the phylogeny of metabolism in order to understand the mass exponent of energy metabolism. Resp Physiol. 1984;55:1–9.
95.
go back to reference Mcmohan TA, Bonner JT. Proportions and size. In: On size and life. New York: Scientific American Library; 1983. p. 25–67. Mcmohan TA, Bonner JT. Proportions and size. In: On size and life. New York: Scientific American Library; 1983. p. 25–67.
96.
go back to reference Veal GJ, Nguyen L, Paci A, et al. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer. 2012;48:3063–72.PubMed Veal GJ, Nguyen L, Paci A, et al. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer. 2012;48:3063–72.PubMed
97.
go back to reference Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther. 2010;87:270–1.PubMed Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther. 2010;87:270–1.PubMed
98.
go back to reference Cella M, Gorter de Vries F, Burger D, et al. Model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther. 2010;87:294–302.PubMed Cella M, Gorter de Vries F, Burger D, et al. Model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther. 2010;87:294–302.PubMed
99.
go back to reference Cella M, Kloprogge F, Danhof M, et al. Dosing rationale for fixed-dose combinations in children: shooting from the hip? Clin Pharmacol Ther. 2012;91:718–25.PubMed Cella M, Kloprogge F, Danhof M, et al. Dosing rationale for fixed-dose combinations in children: shooting from the hip? Clin Pharmacol Ther. 2012;91:718–25.PubMed
100.
go back to reference Alcorn J, McNamara PJ. Using ontogeny information to build predictive models for drug elimination. Drug Discov Today. 2008;13:507–12.PubMed Alcorn J, McNamara PJ. Using ontogeny information to build predictive models for drug elimination. Drug Discov Today. 2008;13:507–12.PubMed
101.
go back to reference Li F, Nandy P, Chien S, et al. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother. 2010;54:375–9.PubMedCentralPubMed Li F, Nandy P, Chien S, et al. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother. 2010;54:375–9.PubMedCentralPubMed
102.
go back to reference Cella M, Knibbe C, de Wildt SN, et al. Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models. Br J Clin Pharmacol. 2012;74:525–35.PubMedCentralPubMed Cella M, Knibbe C, de Wildt SN, et al. Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models. Br J Clin Pharmacol. 2012;74:525–35.PubMedCentralPubMed
103.
go back to reference Cella M, Danhof M, Della Pasqua O. Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children. Br J Clin Pharmacol. 2012;74:346–53.PubMedCentralPubMed Cella M, Danhof M, Della Pasqua O. Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children. Br J Clin Pharmacol. 2012;74:346–53.PubMedCentralPubMed
104.
go back to reference Meibohm B, Läer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7:E475–87.PubMedCentralPubMed Meibohm B, Läer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7:E475–87.PubMedCentralPubMed
105.
go back to reference Björkman S, Collins P. Project on Factor VIII/Factor IX Pharmacokinetics of the Factor VIII/Factor IX Scientific and Standardization Committee of the ISTH. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost. 2013;11:180–2.PubMed Björkman S, Collins P. Project on Factor VIII/Factor IX Pharmacokinetics of the Factor VIII/Factor IX Scientific and Standardization Committee of the ISTH. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost. 2013;11:180–2.PubMed
106.
go back to reference Bjorkman S. Evaluation of the TCI Works Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia. 2011;17:e239–40.PubMed Bjorkman S. Evaluation of the TCI Works Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia. 2011;17:e239–40.PubMed
107.
go back to reference Mahmood I. A Bayesian approach for the estimation of pharmacokinetic parameters in children. Am J Ther. 2003;10:88–92.PubMed Mahmood I. A Bayesian approach for the estimation of pharmacokinetic parameters in children. Am J Ther. 2003;10:88–92.PubMed
108.
go back to reference Mahmood I. Limited sampling model for the estimation of pharmacokinetic parameters in children. Ther Drug Monit. 2000;22:532–6.PubMed Mahmood I. Limited sampling model for the estimation of pharmacokinetic parameters in children. Ther Drug Monit. 2000;22:532–6.PubMed
109.
go back to reference Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931–56.PubMed Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931–56.PubMed
110.
go back to reference Jones HM, Parrott N, Jorga K, et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet. 2006;45:511–42.PubMed Jones HM, Parrott N, Jorga K, et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet. 2006;45:511–42.PubMed
111.
go back to reference Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008;4:1143–52.PubMed Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008;4:1143–52.PubMed
112.
go back to reference Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.PubMed Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.PubMed
113.
go back to reference Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013 (Epub ahead of print). Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013 (Epub ahead of print).
114.
go back to reference Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39:711–23.PubMedCentralPubMed Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39:711–23.PubMedCentralPubMed
115.
go back to reference Jiang XL, Zhao P, Barrett JS, et al. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol. 2013;16(2):e80. Jiang XL, Zhao P, Barrett JS, et al. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol. 2013;16(2):e80.
116.
go back to reference Edginton AN. Knowledge-driven approaches for the guidance of first-in-children dosing. Paediatr Anaesth. 2011;21:206–13.PubMed Edginton AN. Knowledge-driven approaches for the guidance of first-in-children dosing. Paediatr Anaesth. 2011;21:206–13.PubMed
117.
go back to reference Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15:455–64.PubMedCentralPubMed Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15:455–64.PubMedCentralPubMed
118.
go back to reference Leong R, Vieira ML, Zhao P, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91:926–31.PubMed Leong R, Vieira ML, Zhao P, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91:926–31.PubMed
119.
go back to reference Edginton AN, Willmann S. Physiology-based versus allometric scaling of clearance in children: an eliminating process based comparison. Paediatr Perinat Drug Ther. 2006;7:146–53. Edginton AN, Willmann S. Physiology-based versus allometric scaling of clearance in children: an eliminating process based comparison. Paediatr Perinat Drug Ther. 2006;7:146–53.
120.
go back to reference Green B, Dufful SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119–33.PubMedCentralPubMed Green B, Dufful SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119–33.PubMedCentralPubMed
121.
go back to reference Zavorsky GS. Cardiopulmonary aspects of obesity in women. Obstet Gynecol Clin North Am. 2009;36:267–84.PubMed Zavorsky GS. Cardiopulmonary aspects of obesity in women. Obstet Gynecol Clin North Am. 2009;36:267–84.PubMed
122.
go back to reference Mahmood I. Prediction of clearance and volume of distribution in the obese from normal weight subjects: an allometric approach. Clin Pharmacokinet. 2012;51:527–42.PubMed Mahmood I. Prediction of clearance and volume of distribution in the obese from normal weight subjects: an allometric approach. Clin Pharmacokinet. 2012;51:527–42.PubMed
123.
go back to reference Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32:856–68.PubMed Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32:856–68.PubMed
124.
go back to reference Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed. 2010;95:112–7.PubMed Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed. 2010;95:112–7.PubMed
125.
go back to reference Kendrick JG, Carr RR, Ensom MH. Pharmacokinetics and drug dosing in obese children. J Pediatr Pharmacol Ther. 2010;15:94–109.PubMedCentralPubMed Kendrick JG, Carr RR, Ensom MH. Pharmacokinetics and drug dosing in obese children. J Pediatr Pharmacol Ther. 2010;15:94–109.PubMedCentralPubMed
126.
go back to reference Koshida R, Nakashima E, Taniguchi N, et al. Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. Pharm Res. 1989;6:486–91.PubMed Koshida R, Nakashima E, Taniguchi N, et al. Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. Pharm Res. 1989;6:486–91.PubMed
127.
go back to reference Diepstraten J, Chidambaran V, Sadhasivam S, et al. An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol. 2013;2:e73.PubMed Diepstraten J, Chidambaran V, Sadhasivam S, et al. An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol. 2013;2:e73.PubMed
128.
go back to reference Lewis TV, Johnson PN, Nebbia AM, et al. Increased enoxaparin dosing is required for obese children. Pediatrics. 2011;127:e787–90.PubMed Lewis TV, Johnson PN, Nebbia AM, et al. Increased enoxaparin dosing is required for obese children. Pediatrics. 2011;127:e787–90.PubMed
129.
go back to reference Moffett BS, Kim S, Edwards MS. Vancomycin dosing in obese pediatric patients. Clin Pediatr (Phila). 2011;50:442–6. Moffett BS, Kim S, Edwards MS. Vancomycin dosing in obese pediatric patients. Clin Pediatr (Phila). 2011;50:442–6.
130.
go back to reference Heble DE Jr, McPherson C, Nelson MP, et al. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy. 2013 (Epub ahead of print). Heble DE Jr, McPherson C, Nelson MP, et al. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy. 2013 (Epub ahead of print).
131.
go back to reference Miller M, Miller JL, Hagemann TM, et al. Vancomycin dosage in overweight and obese children. Am J Health Syst Pharm. 2011;68:2062–8.PubMed Miller M, Miller JL, Hagemann TM, et al. Vancomycin dosage in overweight and obese children. Am J Health Syst Pharm. 2011;68:2062–8.PubMed
Metadata
Title
Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings
Author
Iftekhar Mahmood
Publication date
01-04-2014
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 4/2014
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-014-0134-5

Other articles of this Issue 4/2014

Clinical Pharmacokinetics 4/2014 Go to the issue